Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.
The current price of TECH is $55.00 USD — it has increased by +1.85% in the past 24 hours. Watch Bio-Techne stock price performance more closely on the chart.
What is Bio-Techne stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bio-Techne stocks are traded under the ticker TECH.
Is Bio-Techne stock price growing?▼
TECH stock has risen by +4.46% compared to the previous week, the month change is a +27.02% rise, over the last year Bio-Techne has showed a +8.87% increase.
What is Bio-Techne market cap?▼
Today Bio-Techne has the market capitalization of 8.6B
When is the next Bio-Techne earnings date?▼
Bio-Techne is going to release the next earnings report on August 11, 2026.
What were Bio-Techne earnings last quarter?▼
TECH earnings for the last quarter are 0.53 USD per share, whereas the estimation was 0.53 USD resulting in a -0.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bio-Techne revenue for the last year?▼
Bio-Techne revenue for the last year amounts to 2.44B USD.
What is Bio-Techne net income for the last year?▼
TECH net income for the last year is 146.8M USD.
Does Bio-Techne pay dividends?▼
Yes, TECH dividends are paid quarterly. The last dividend per share was 0.08 USD. As of today, Dividend Yield (FWD)% is 0.59%.
How many employees does Bio-Techne have?▼
As of June 15, 2026, the company has 3,100 employees.
In which sector is Bio-Techne located?▼
Bio-Techne operates in the Health & Wellness sector.
When did Bio-Techne complete a stock split?▼
The last stock split for Bio-Techne was on November 30, 2022 with a ratio of 4:1.
Where is Bio-Techne headquartered?▼
Bio-Techne is headquartered in Minneapolis, United States.